5Adult inflammatory myopathies
Section snippets
Epidemiology
The inflammatory myopathies are rare. The incidence rate of PM is estimated to be between 2.18×10−6 and 7.7×10−6. Oddis and Medsger found an increasing incidence in two separate studies performed 20 years apart, although this may reflect better diagnostic accuracy rather than a true increase.6., 7. The incidence appears to increase with age, highest rates being seen in the 35–44 and 55–64-year-old age groups. There is a paucity of epidemiological studies that address the incidence among
Pathogenesis
The pathogenesis of the autoimmune inflammatory myopathies remains elusive and the mechanism of cell injury in inflammatory myopathy unclear. Although there are cases of myositis in which frank inflammation is missing on muscle biopsy, it is generally accepted that inflammation is the major cause of muscle damage and that autoimmunity lies at the root of the inflammation. Autoantibodies—albeit not directed at muscle specific antigens—are found in the majority of cases of PM and DM, but not
Diagnosis
The definitive diagnosis of an inflammatory requires a muscle biopsy. A biopsy should be performed on every patient in whom the diagnosis of an inflammatory myopathy is considered, in order not only to confirm the diagnosis, but also to rule out the many conditions that resemble myositis clinically. In addition to a careful history, family history and laboratory tests, both electromyography and imaging studies, particularly magnetic resonance imaging (MRI), may serve as useful adjuncts to
Treatment
It is well known that there is a high morbidity and substantial mortality associated with the inflammatory myopathies so the prompt recognition and therapy of these diseases is essential. One series performed a retrospective chart review and determined the overall mortality rate to be as high as 22%, largely as a result of cancer and pulmonary complications.55 DM has to date proved the most treatable inflammatory myopathy, responding to steroids, intravenous immunoglobulin or immunosuppressants
Summary
The inflammatory myopathies of adults-principally DM, PM and IBM-are uncommon, have a high morbidity; are not infrequently the first sign of an associated malignancy; may be part of another connective tissue disease and resemble a number of rarer non-inflammatory diseases from which it is essential to distinguish them. Biopsy is an essential part of the work-up of every patient in whom an inflammatory myopathy is considered, as is a careful search for a possible associated malignancy. The use
References (69)
- et al.
The epidemiology of polymyositis
American Journal of Medicine
(1970) - et al.
Workshop on inflammatory myopathy Bethesda, 5–6 April 2000
Neuromuscular Disorders
(2001) - et al.
Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle
Lancet
(1992) - et al.
Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation
Chest
(2003) - et al.
Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis
Journal of the American Academy of Dermatology
(2003) Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis, and inclusion body myositis
Rheumatic Disease Clinics of North America
(1994)- et al.
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study
Lancet
(2001) - et al.
Cutaneous mucinosis in dermatomyositis associated with a malignant tumor
Journal of the American Academy of Dermatology
(2003) - et al.
High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis
Seminars in Arthritis and Rheumatism
(1998) - et al.
Dermatomyositis associated with urachal adenocarcinoma
Journal of Urology
(2002)
Paraneoplastic polymyositis in recurring adrenal gland carcinoma
Lancet Neurology
Serum CA-125 screening for ovarian cancer in patients with dermatomyositis
Gynecological Oncology
Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy
American Journal of Medicine
Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis
Journal of Neurological Science
Polymyositis and dermatomyositis II
New England Journal of Medicine
Polymyositis and dermatomyositis I
New England Journal of Medicine
Classification criteria for polymyositis and dermatomyositis [see comments]
Journal of Rheumatology
Classification criteria for the idiopathic inflammatory myopathies
Current Opinion in Rheumatology
Inclusion body myositis and myopathies
Annals of Neurology
Incidence of polymyositis–dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982
Journal of Rheumatology
Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease
Arthritis and Rheumatism
Defining clinical improvement in adult and juvenile myositis
Journal of Rheumatology
Immunological capabilities of skeletal muscle cells
Acta Physiologica Scandinavica
Immune effector mechanisms in inflammatory myopathies
Research Publications—Association for Research in Nervous and Mental Disease
Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients
Journal of Immunology
Polymyositis: an overdiagnosed entity
Neurology
Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis
Journal of Clinical Investigation
Cellular immune mechanisms in inflammatory myopathies
Current Opinion in Rheumatology
Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity
Journal of Experimental Medicine
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells
Journal of Experimental Medicine
Unfolding story of inclusion-body myositis and myopathies: role of misfolded proteins, amyloid-beta, cholesterol, and aging
Journal of Child Neurology
Transthyretin Val122Ile, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle
Neurology
The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy
Nature Genetics
The idiopathic inflammatory myopathies: spectrum of MR imaging findings
Radiographics
Cited by (43)
Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group
2020, Seminars in Arthritis and RheumatismCitation Excerpt :The idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases characterized by skeletal muscle involvement leading to muscle weakness [1,2,3].
Assessment of inpatients with idiopathic inflammatory myopathies: A 10-year single unit experience
2019, Egyptian RheumatologistCitation Excerpt :Only 35% of the patients had an assessed ENA profile available in their admission documents, so it seems that some of the patients with PM and positive ANA might have had the diagnoses of overlap myositis and it should be evaluated further although their number were not so high. It has been reported that the incidence of IIM increased with age; the highest seen in the age groups of 35–44 and 55–64 years [15]. The mean age for admitted patients was comparable with another study [16].
Muscle Disease and Dysfunction
2016, Pathology and Intervention in Musculoskeletal RehabilitationSurvival and cancer risk in an unselected and complete Norwegian idiopathic inflammatory myopathy cohort
2015, Seminars in Arthritis and RheumatismCitation Excerpt :Idiopathic inflammatory myopathies (IIM) are chronic, systemic disorders of unknown aetiology. They are defined by progressive loss of striated muscle tissue and include three major clinical syndromes: dermatomyositis (DM), polymyositis (PM) and sporadic inclusion body myositis (sIBM) [1–5]. PM and DM cause symmetrical and proximal weakness, while sIBM is more asymmetric and involves the quadriceps and finger flexors [6–8].
Management of inflammatory muscle disease
2015, Rheumatology: Sixth Edition